Silence Therapeutics to proceed with AIM delisting next week
26th Nov 2021 09:53
(Sharecast News) - Silence Therapeutics updated the market on the planned cancellation of its shares on AIM on Friday, which it originally announced on 15 October.
Read moreRevenue, expenses rise in third quarter for Silence Therapeutics
16th Nov 2021 11:39
(Sharecast News) - Silence Therapeutics said on Tuesday that its revenue increased by £1.2m year-on-year in its third quarter, as a result of the further advancement of its partner programmes, as well as the introduction of additional programmes with its partners.
Read moreFrazier Life Sciences becomes 'important' new Silence Therapeutics shareholder
5th Nov 2021 11:39
(Sharecast News) - Novel short interfering ribonucleic acid (siRNA) therapy developer Silence Therapeutics announced on Friday that healthcare-focussed investor Frazier Life Sciences Public Fund had purchased about $20m of its existing shares.
Read moreSilence Therapeutics inks collaboration deal with Hansoh Pharmaceutical
15th Oct 2021 12:23
(Sharecast News) - Silence Therapeutics announced a collaboration with Hansoh Pharmaceutical Group on Friday, to develop short interfering ribonucleic acids (siRNAs) for three undisclosed targets, leveraging its proprietary 'mRNAi GOLD' platform.
Read moreSilence promotes John Strafford to head new product development
1st Sep 2021 09:30
(Sharecast News) - Silence Therapeutics announced the appointment of John Strafford to the newly-created role of senior vice-president of business development, alliance management and new product development on Wednesday, effective immediately.
Read moreSilence Therapeutics losses widen as it progresses programmes
12th Aug 2021 09:37
(Sharecast News) - Silence Therapeutics reported revenues from collaborations of £5.8m in its first half on Thursday, up from £1.1m year-on-year, which it put down to its work with AstraZeneca and Mallinckrodt.
Read moreSilence Therapeutics to present positive data from 'SLN124'
7th Jun 2021 08:51
(Sharecast News) - Silence Therapeutics announced on Monday that it would present data showing the potential for 'SLN124' to address a range of hematological diseases by targeting the liver-expressed gene TMPRSS6.
Read moreSilence Therapeutics receives remaining $40m from AstraZeneca partnership
25th May 2021 12:35
(Sharecast News) - Silence Therapeutics announced receipt of the remaining $40m (£28.24m) from AstraZeneca on Tuesday, due as part of AstraZeneca's $80m cash and equity investment for the siRNA collaboration announced in March 2020.
Read moreSilence Therapeutics reveals positive data from SLN124 study
19th May 2021 10:20
(Sharecast News) - Silence Therapeutics announced positive topline data from the 'GEMINI' phase 1 study of its wholly-owned product candidate 'SLN124' in healthy volunteers on Wednesday.
Read moreSilence Therapeutics doses first patient in 'GEMINI II' study
29th Apr 2021 09:48
(Sharecast News) - Silence Therapeutics announced on Thursday that the first patient has been dosed in the 'GEMINI II' phase 1 clinical study of its wholly-owned lead product candidate, SLN124, for the treatment of 'iron-loading' anemias, thalassemia and myelodysplastic syndrome (MDS).
Read moreSilence Therapeutics gets $2m milestone payment from Mallinckrodt
28th Apr 2021 13:33
(Sharecast News) - Silence Therapeutics has achieved another research milestone as part of its ongoing RNAi collaboration with Mallinckrodt for complement-mediated diseases, it announced on Wednesday, triggering a further $2m payment.
Read moreSilence to get $2m milestone payment from Mallinckrodt
26th Feb 2021 09:06
(Sharecast News) - Silence Therapeutics announced on Friday that it would receive a $2m (£1.43m) milestone payment following the start of work on a third target being explored under its ongoing RNAi research collaboration with Mallinckrodt, for the treatment of complement pathway-mediated diseases.
Read moreSilence Therapeutics begins dosing in lipoprotein treatment trial
17th Feb 2021 08:12
(Sharecast News) - Silence Therapeutics has started dosing subjects in the 'APOLLO' phase 1 clinical study of its wholly-owned lead product candidate 'SLN360', it announced on Wednesday, for the treatment of elevated lipoprotein-a (Lp(a)) levels.
Read moreSilence Therapeutics raises ?33m to support pipeline development
5th Feb 2021 09:04
(Sharecast News) - Novel therapeutics developer Silence Therapeutics announced an oversubscribed private placement of 2,022,218 American depositary shares (ADSs) on Friday, raising £33m to support the development of its pipeline.
Read moreSilence Therapeutics taps Craig Tooman for CFO
6th Jan 2021 08:06
(Sharecast News) - Drug discovery outfit Silence Therapeutics has named Craig Tooman as its new chief financial officer.
Read more